Mipharm To Develop Pharmadigm Product In Italy

Pharmadigm Inc. has entered into an agreement with Mipharm S.p.A. (Milan, Italy) for the European development of Pharmadigm's lead product, PB005, an injectable pharmaceutical product for use by hospitals in the management of acute inflammation. Under the terms of the agreement, Mipharm will make an investment in Pharmadigm equity and will fund clinical trials and the registration of PB005 in Europe in the fields of acute asthma, burn therapy and surgical wound healing.

In return, Mipharm receives the exclusive right to market PB005 in Italy, The Vatican and San Marino, while Pharmadigm retains the right to market or license PB005 for the rest of Europe.

Pharmadigm's PB005, an injectable dosage formulation of the adrenal steroid dehydroepiandrosterone (DHEAS), is initially being tested in three Phase II clinical trials in the United States to evaluate its utility in the management of acute asthmatic attack, severe burns and surgical wound healing.

For more information: Pharmadigm, 2401 Foothill Drive, Salt Lake City, Utah 84109. Telephone: 801-464-6100. Fax: 801-464-6116.